ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
Key Highlights
- ➤ARR-217 Phase 1 initial safety and efficacy data selected for ESMO rapid oral presentation
- ➤ARR-217 data presentation scheduled for October 25, 2026, in Madrid
- ➤ArriVent will host an October 26 webinar discussing ARR-217 program data
- ➤ArriVent holds worldwide ex-Greater China rights to develop and commercialize ARR-217
* First-in-human data for ARR-217 selected as a late-breaking oral presentation * ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program NEWTOWN SQUARE, Pa., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that initial safety and efficacy data from the Phase 1 (NCT07066657) study of CDH17-targeted ADC ARR-217 (MRG007) in patients with gastrointestinal cancers, will be presented in a rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain, on October 23-27, 2026. ArriVent plans to host a virtual webinar on October 26, 2026 at 8 am ET to discuss the data and ARR-217 program. To register for the event, click here.
Get started
Create a free account to read the full story.